Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 PatientsArticle Published on 2022-11-012022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 치료기술, [키워드] acute respiratory syndrome addressed baseline carrier Cell culture clinical coronavirus 2 coronavirus disease Coronavirus-2 coughing COVID-19 COVID-19 patient Culture Cycle threshold value evaluate fomite transmission Hospitalized Infectious virus initiated Intensive laboratory parameter occur oropharyngeal swab pandemic Patient polymerase chain positive Quantitative respiratory risk Saliva SARS-CoV-2 SARS-CoV-2 transmission Sequencing single-center stability surface stability. Swab Transmission unlikely Viral load viral ribonucleic acid virus virus transmission [DOI] 10.1093/infdis/jiac170 PMC 바로가기
DeepLPI: a novel deep learning-based model for protein-ligand interaction prediction for drug repurposingArticle Published on 2022-10-282022-11-16 Journal: Scientific Reports [Category] 신약개발, [키워드] applied approved drug baseline CNN computational method COVID-19 dataset Davis downloaded drug-target interaction drugs Features high accuracy Interaction memory molecular patients predict protein-ligand interaction Research sequence target protein target protein sequence vector [DOI] 10.1038/s41598-022-23014-1 PMC 바로가기
Association of Results of Four Lateral Flow Antibody Tests with Subsequent SARS-CoV-2 InfectionArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% confidence interval acute respiratory syndrome adjusted anti-SARS-CoV-2 IgG antibody assist association baseline Cohort cohort study conducted coronavirus Coverage COVID COVID-19 demonstrated disease risk England fire Flow Follow-up hospital IgG Immunity immunoassay immunoassays incidence rate individual Infection investigated Laboratory laboratory assays Lateral Lateral flow device lateral flow device. lateral flow immunoassay Lateral flow test LFIA LFIAs management microbiologically natural infection pandemic participant point-of-care test Poisson regression model Police service Population screening positive predicted prospective cohort study Protective Rapid Rapid test rapid test cassette recruitment Research Result risk risk factor Roche SARS-CoV-2 SARS-CoV-2 disease SARS-CoV-2 IgG SARS-COV-2 infection specificity subsequent Surescreen susceptibility symptomatic SARS-CoV-2 infection Test threshold United Kingdom unvaccinated populations Vaccine was tested [DOI] 10.1128/spectrum.02468-22 PMC 바로가기
Aerosolized Hydrogen Peroxide Decontamination of N95 Respirators, with Fit-Testing and Viral Inactivation, Demonstrates Feasibility for Reuse during the COVID-19 PandemicArticle Published on 2022-10-262022-11-15 Journal: mSphere [Category] COVID19(2023년), SARS, 진단, [키워드] absorbed acute respiratory syndrome aerosolized hydrogen peroxide Aerosols Bacterial baseline Biosafety Level 3 BSL3 Care Clinical use comparable coronavirus COVID-19 COVID-19 pandemic coxsackievirus Critical CURIS decontamination develop Disinfection effective Efficiency evaluated experimental validation External filtering facepiece (FFP) respirators (FFR) filtration fit-testing greater Health Health care worker herpes simplex HSV-1 hydrogen hydrogen peroxide inactivation include indicated limit limitation Multiple N95 respirator N95 respirators occupational pandemic pathogen peroxide Personal protective equipment Protective provided Quantitative Research Respirator respirators respiratory droplet Result reuse Safe Safety SARS-CoV-2 SARS-CoV2 spores Sterilization These data transmitted Treatment viral inactivation virologic testing virus virus virus. while [DOI] 10.1128/msphere.00303-22 PMC 바로가기
Comparable diagnostic accuracy of SARS-CoV-2 Spike RBD and N-specific IgG tests to determine pre-vaccination nation-wide baseline seroprevalence in MexicoArticle Published on 2022-10-262022-11-15 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Accuracy anti-nucleoprotein anti-RBD antibody marker baseline commercial immunoassay comparable country COVID-19 pandemic determine diagnostic Disease progression ELISA protocol Epidemic epidemiological heterogeneity IgG IgG test implementation Local marker natural infection positive post-symptom onset pre-vaccination Prevalence protocol RBD SARS-CoV-2 SARS-CoV-2 spike protein serological serological survey significantly spike vaccination Vaccination strategy [DOI] 10.1038/s41598-022-22146-8 PMC 바로가기
Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndromeArticle Published on 2022-10-202022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] analyzed Anti-viral anti-viral antibody antibody Antibody Response baseline chronic disease CMV cohorts COVID-19 EBV elevated fatigue healthy donor herpesvirus herpesvirus reactivation HERV HERV-K HHV6A HSV2 IgG immunoassay latent virus majority ME/CFS mechanisms multiplex myalgic encephalomyelitis/chronic fatigue syndrome. nuclear oral mucosa overlap Patient plasma Post-viral fatigue Reactivation retrovirus risk factor Saliva SARS-COV-2 infection shown significantly sustained Symptom syndrome systemically triggered unique viral infection virus virus [DOI] 10.3389/fimmu.2022.949787 PMC 바로가기
Individual-based modeling reveals that the COVID-19 isolation period can be shortened by community vaccinationArticle Published on 2022-10-202022-11-16 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI approach B.1.617.2 baseline BNT162b2 vaccine booster vaccination Community Contact COVID-19 Delta Effect effective vaccine emotional Impact individual infected individual infected individuals Infection Isolation less likelihood mitigate nonpharmaceutical intervention occur outbreak profile Psychological quarantine reduce reveal risk Secondary infection subsequent sustained the patient the SARS-CoV-2 Transmission transmission of SARS-CoV-2 vaccination Vaccine-induced immunity variant Viral load [DOI] 10.1038/s41598-022-21645-y PMC 바로가기
Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysisArticle Published on 2022-10-202022-11-15 Journal: Scientific Reports [Category] COVID19(2023년), meta-analysis, SARS, 변종, 진단, [키워드] absolute reduction article baseline Bayesian comparable Comparative COVID-19 Effect effective Effectiveness Efficacy Evidence expected generalisability healthcare high risk hospitalisation ICU admission identify individual infected individual infected with SARS-CoV-2 invasive ventilation moderate monoclonal antibody Mortality network Network meta-analysis neutralising outcome Pairwise comparison patient population patients patients treated Placebo predict Rate RCT reaction reduce mortality reducing reduction in relative risk risk reduction serious AE severe COVID-19 statistically significant reduction systematic review therapy treatment effect vaccination variant [DOI] 10.1038/s41598-022-22431-6 PMC 바로가기
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19Article Published on 2022-10-192022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% CI Administered administration Adverse affected analysed antiviral therapy Antiviral treatment ARMS baseline changed Combination combination therapy concentrations conducted coronavirus 2 COVID-19 COVID-19 pandemic Day Dose escalation doses double-blind double-blind trial drug level effective Efficacy evaluate the effect event Favipiravir healthy Interaction Lopinavir-ritonavir measure monotherapy Odds ratio Outpatient participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial placebos plasma primary analysis Primary outcome provided randomised recruited reduced respiratory SARS-CoV-2 SARS-CoV-2 viral load significant interaction significantly study population symptom onset the mean trajectory Treatment undetectable United Kingdom Viral load virus [DOI] 10.1371/journal.pmed.1004120 PMC 바로가기
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a PartArticle Published on 2022-10-182022-11-15 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome All adverse event Asymptomatic baseline clinical coronavirus coronavirus disease COVID-19 Culture demonstrated double-blind Efficacy and safety ensitrelvir fumaric acid greater group groups intention-to-treat population Japan Japanese log median time Mild Mild-to-moderate moderate multicenter novel oral Part Patient phase phase 2/3 Placebo positive Primary outcome proof-of-concept study protease Protease inhibitor Randomized receive reduced registry Result S-217622 SARS-CoV-2 SARS-CoV-2 3C-like protease inhibitor SARS-CoV-2 clearance SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV-2 viral the SARS-CoV-2 tissue Treatment viral clearance Viral RNA viral titer viral titer. [DOI] 10.1128/aac.00697-22 PMC 바로가기